Pfizer’s Modified mRNA Quadrivalent Influenza Vaccine Demonstrates 34.5% Relative Efficacy vs Licensed Inactivated Vaccine in Phase 3 Trial
Highlights
– Pfizer’s modified nucleoside mRNA quadrivalent influenza vaccine showed a statistically superior relative efficacy of 34.5% (95% CI 7.4–53.9) versus a licensed inactivated quadrivalent vaccine in adults 18–64 years during the 2022–2023 season.
– Efficacy and HAI noninferiority were demonstrated for influenza A/H3N2 and A/H1N1 strains but not for influenza B strains; most cases in the trial were A strains.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.